| 发明名称 | Platform drug delivery system utilizing crystal engineering and theanine dissolution | ||
| 摘要 | A platform drug delivery system and a method of improving the delivery of low solubility pharmaceuticals utilizing crystal engineering and Theanine dissolution resulting in enhanced bioactivity, dissolution rate, and solid state stability. | ||
| 申请公布号 | US9603937(B2) | 申请公布日期 | 2017.03.28 |
| 申请号 | US201514642191 | 申请日期 | 2015.03.09 |
| 申请人 | Theaprin Pharmaceuticals Inc. | 发明人 | Brittain Harry G.;Felice Philip V. |
| 分类号 | A61K47/18;A61K47/48;A61K31/704;A61K31/13;A61K31/137;A61K31/192;A61K31/198;A61K31/277;A61K31/4045;A61K31/4164;A61K31/4196;A61K31/426;A61K31/43;A61K31/445;A61K31/4745;A61K31/48;A61K31/496;A61K31/4985;A61K31/506;A61K31/522;A61K31/536;A61K31/545;A61K31/546;A61K31/549;A61K31/573;A61K31/635;A61K31/7048;A61K31/7072;A61K38/12 | 主分类号 | A61K47/18 |
| 代理机构 | Nataro, Michalos & Zaccaria P.C. | 代理人 | Nataro, Michalos & Zaccaria P.C. |
| 主权项 | 1. A cocrystal of L-theanine; and doxorubicin, wherein said cocrystal is characterized as having an X-ray powder diffraction pattern with peaks (2θ) at 13.6, 18.2, 19.8, 22.0, 22.5, 25, and 38.2 degrees. | ||
| 地址 | Hauppauge NY US | ||